Application of ZNF514 in the diagnosis and treatment of lung adenocarcinoma

By targeting the ZNF514 and COL1A1 signaling pathways, it inhibits the invasion and metastasis of lung adenocarcinoma cells, improves the sensitivity of cisplatin, solves the problem of chemotherapy resistance of lung adenocarcinoma, and significantly improves the prognosis of patients.

CN118291622BActive Publication Date: 2024-11-12JINAN CENTER HOSPITAL
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410414913.1
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-04-08
Publication Date
2024-11-12
Estimated Expiration
2044-04-08

AI Technical Summary

Technical Problem

Patients with lung adenocarcinoma have high resistance to cisplatin chemotherapy, and the prior art is difficult to effectively target key molecules, resulting in poor treatment results.

Method used

Research has found that ZNF514, as an important transcriptional repressor, prevents the invasion and metastasis of cancer cells by inhibiting COL1A1 expression, and increases sensitivity to cisplatin, providing methods and products for detecting the expression level of ZNF514 for diagnosis and treatment of lungs. Adenocarcinoma.

Benefits of technology

By increasing the expression level of ZNF514, the growth and metastasis of lung adenocarcinoma cells are significantly inhibited, the sensitivity to cisplatin is enhanced, and the prognosis of patients is improved.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118291622B_ABST
    Figure CN118291622B_ABST
Patent Text Reader

Abstract

The present invention belongs to the field of biomedicine and molecular biology technology, and specifically relates to the application of ZNF514 in the diagnosis and treatment of lung adenocarcinoma. The present invention has found that ZNF514 is downregulated in LUAD tissues and cell lines, and low expression of ZNF514 is significantly associated with poor prognosis. ZNF514 overexpression can inhibit tumor growth in LUAD cell lines, tumor organoids and xenograft mouse models. Mechanistically, it was determined that ZNF514 is an important transcriptional repressor of LUAD. ZNF514 inhibits EMT progression by transcriptionally repressing COL1A1 expression, thereby significantly inhibiting LUAD growth, invasion and resistance to DDP.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the technical field of biomolecular medicine and molecular biology, and specifically relates to the application of ZNF514 in the diagnosis and treatment of lung adenocarcinoma. Background Art

[0002] Lung adenocarcinoma (LUAD) is a major subtype of lung cancer, characterized by high metastasis and high mortality. For most patients with advanced LUAD, cisplatin (DDP)-based chemotherapy drugs remain the first-line treatment. DDP can induce tumor cell apoptosis by cross-linking DNA chains, thereby destroying the structure and function of DNA. However, most LUAD patients will develop DDP resistance during treatment. Therefore, discovering key molecules associated with tumor DDP resistance and metastasis will provide important targets for the treatment of LUAD, which is a prerequisite for the development of new diagnostic and therapeutic biomarkers to obtain better patient prognosis and has important clinical value.

[0003] The progression of LUAD involves many key steps, and extracellular matrix (ECM) remodeling is the most important process. ECM is the main component of the intercellular matrix and promotes the survival, proliferation, metastasis, angiogenesis, and immune escape of cancer cells. The collagen family plays a vital role as an important component of ECM and is widely distributed in mammals. Ectopic expression of collagen family members can change the characteristics of epithelial cells and reshape their morphology and function. This process enhances the separation of cancer cells from the original tumor mass and is also necessary for the initiation of metastasis, thereby enabling cancer cells to enter the bloodstream or lymphatic system and promote their colonization at distant sites. In addition, emerging evidence shows that collagen content is closely related to chemoresistance in LUAD. For example, studies have shown that type I collagen can enhance autocrine signaling through interaction with integrins, thereby promoting cancer cell proliferation, invasion, and drug resistance. In addition, studies have shown that high levels of collagen deposition contribute to increased ECM stiffness, hindering drug transport and reducing sensitivity to anticancer treatment. Therefore, targeting collagen-induced chemoresistance is an important way to treat this disease.

[0004] Zinc finger proteins (ZFPs) are transcription factors with finger-like DNA binding functions that play an important role in a variety of biological processes. To date, zinc finger motifs can be divided into eight categories based on their main chain conformation and the secondary structure around the zinc binding site: C2H2-like zinc fingers, knot-like zinc fingers, treble clef zinc fingers, ribbon zinc fingers, Zn2 / Cys6-type zinc fingers, TAZ2-like zinc fingers, zinc ion binding short-loop zinc fingers, and metallothionein zinc fingers. In addition to these zinc finger motifs, ZFPs also contain several domains that play different roles in cell biological processes, including BTB domains, SET domains, and SCAN domains. The structural diversity of zinc finger proteins determines the complexity of their functions.

[0005] Currently, there is increasing evidence that ZFPs are abnormally expressed in various cancer types and are involved in regulating many cancer-related signaling pathways such as p53, Wnt / β-catenin, NF-κB, MAPK, PI3K / AKT, etc., thereby affecting multiple cellular processes such as cell cycle, proliferation, migration, invasion, apoptosis, autophagy, ferritin degradation, metabolism and chemotherapy resistance, and playing a role in the occurrence and development of tumors.

[0006] ZNF514 belongs to the zinc finger protein family; however, due to the lack of any research reports on this molecule, its abnormal expression and biological function in cancer progression remain largely unclear. Summary of the invention

[0007] In order to overcome the above problems, the present invention provides the application of ZNF514 in the diagnosis and treatment of lung adenocarcinoma. The present invention found that ZNF514 was downregulated in LUAD tissues and cell lines, and low expression of ZNF514 was significantly correlated with poor prognosis. ZNF514 overexpression can inhibit tumor growth in LUAD cell lines, tumor organoids and xenograft mouse models. Mechanistically, it was determined that ZNF514 is an important transcriptional repressor of LUAD. ZNF514 inhibits EMT progression by transcriptionally inhibiting COL1A1 expression, thereby significantly inhibiting LUAD growth, invasion and resistance to DDP. Based on the above research results, the present invention is completed.

[0008] The first aspect of the present invention provides the use of a substance for detecting the expression level of the ZNF514 gene and its expression products in the preparation of a product for diagnosing, detecting, monitoring or predicting the progression of lung adenocarcinoma.

[0009] The product can diagnose, detect, monitor or predict the progression of lung adenocarcinoma by monitoring the expression level of ZNF514 gene and / or ZNF514 expression product. The present invention has found through research that ZNF514 is lowly expressed in LUAD tissues and cell lines, and low expression of ZNF514 indicates a later stage of disease and poor patient survival. There is a significant correlation between high expression of ZNF514 mRNA and increased overall survival rate of LUAD patients, with a hazard ratio (HR) of 0.69 and a log-rank P value of 0.00071.

[0010] The second aspect of the present invention provides a product for diagnosing, detecting, monitoring or predicting the progression of lung adenocarcinoma, which comprises a substance for detecting the transcription of ZNF514 in a sample based on a high-throughput sequencing method and / or based on a quantitative PCR method and / or based on a probe hybridization method; or a substance for detecting the expression of ZNF514 protein based on an immunodetection method.

[0011] Preferably, liquid hybridization, Northern hybridization, miRNA expression profile chip, ribozyme protection analysis technology, RAKE method, and in situ hybridization are used to detect the expression (transcription) of ZNF514 gene;

[0012] The immunoassay method preferably includes Western blot, ELISA, colloidal gold test strips and protein chips;

[0013] The sample may be a lung-related sample of a subject, such as lung cells, tissues, blood, lymph fluid, etc.

[0014] The product may be a kit.

[0015] The third aspect of the present invention provides the use of a substance that promotes ZNF514 and its expression product and / or activity increase in at least one of the following b1)-b6):

[0016] b1) Inhibiting the proliferation and metastasis of lung adenocarcinoma cells, or preparing a product for inhibiting the proliferation and metastasis of lung adenocarcinoma cells;

[0017] b2) Inhibiting tumor growth, or preparing products for inhibiting tumor growth;

[0018] b3) inhibiting the expression of COL1A1 in lung adenocarcinoma cells, or preparing a product for inhibiting the expression of COL1A1 in lung adenocarcinoma cells;

[0019] b4) Improving the sensitivity of lung adenocarcinoma to cisplatin after cisplatin chemotherapy resistance, or preparing a product for improving the sensitivity of lung adenocarcinoma to cisplatin after cisplatin chemotherapy resistance;

[0020] b5) combining with cisplatin to inhibit the proliferation and metastasis of lung adenocarcinoma cells, or combining with cisplatin to prepare a product for inhibiting the proliferation and metastasis of lung adenocarcinoma cells;

[0021] b6) Combined with cisplatin to prepare a product for the treatment of lung adenocarcinoma.

[0022] Wherein, the tumor is lung adenocarcinoma.

[0023] A fourth aspect of the present invention provides a composition comprising a substance that promotes the increase of ZNF514 and its expression product and / or activity.

[0024] A fifth aspect of the present invention provides the use of the above composition in any one or more of the following:

[0025] b1) Inhibiting the proliferation and metastasis of lung adenocarcinoma cells, or preparing a product for inhibiting the proliferation and metastasis of lung adenocarcinoma cells;

[0026] b2) Inhibiting tumor growth, or preparing products for inhibiting tumor growth;

[0027] b3) inhibiting the expression of COL1A1 in lung adenocarcinoma cells, or preparing a product for inhibiting the expression of COL1A1 in lung adenocarcinoma cells;

[0028] b4) Improving the sensitivity of lung adenocarcinoma to cisplatin after cisplatin chemotherapy resistance, or preparing a product for improving the sensitivity of lung adenocarcinoma to cisplatin after cisplatin chemotherapy resistance;

[0029] b5) combining with cisplatin to inhibit the proliferation and metastasis of lung adenocarcinoma cells, or combining with cisplatin to prepare a product for inhibiting the proliferation and metastasis of lung adenocarcinoma cells;

[0030] b6) Combined with cisplatin to prepare a product for the treatment of lung adenocarcinoma.

[0031] Wherein, the tumor is lung adenocarcinoma.

[0032] According to the present invention, when the product is a medicine, the medicine further comprises at least one inactive pharmaceutical ingredient.

[0033] The inactive ingredients of the drug can be carriers, excipients and diluents commonly used in pharmacy. Moreover, according to the usual methods, the drug can be made into oral preparations, external preparations, suppositories and sterile injection solutions in the form of powders, granules, tablets, capsules, suspensions, emulsions, syrups, sprays, etc.

[0034] The non-drug active ingredients such as carriers, excipients and diluents that may be included are well known in the art, and those skilled in the art can determine whether they meet clinical standards.

[0035] Preferably, the carrier, excipient and diluent include but are not limited to lactose, glucose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, gum arabic, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methyl hydroxybenzoate, propyl hydroxybenzoate, talc, magnesium stearate and mineral oil.

[0036] Preferably, the medicine of the present invention can be applied to the body by known means. For example, it can be delivered to the tissue of interest by systemic intravenous delivery or local injection. It can be applied optionally via intravenous, percutaneous, intranasal, mucosal or other delivery methods. Such application can be carried out via single dose or multiple doses. It will be appreciated by those skilled in the art that the actual dose to be applied in the present invention can vary depending on various factors to a great extent, such as target cells, biological types or their tissues, the general condition of the subject to be treated, the route of administration, the mode of administration, etc.

[0037] Preferably, the drug administration subjects can be humans and non-human mammals, such as mice, rats, guinea pigs, rabbits, dogs, monkeys, gorillas, etc.

[0038] The beneficial effects of the present invention are:

[0039] The present study found that ZNF514 was downregulated in LUAD tissues and cell lines, and low expression of ZNF514 was significantly associated with poor prognosis. ZNF514 overexpression can inhibit tumor growth in LUAD cell lines, tumor organoids, and xenograft mouse models. Mechanistically, ZNF514 was determined to be an important transcriptional repressor of LUAD. This is mainly because ZNF514 inhibits EMT progression by transcriptionally inhibiting COL1A1 expression, thereby significantly inhibiting LUAD growth, invasion, and resistance to DDP. At the same time, the study found that when ZNF514 is used in combination with DDP, the therapeutic effect on LUAD is better. BRIEF DESCRIPTION OF THE DRAWINGS

[0040] The accompanying drawings in the specification, which constitute a part of the present invention, are used to provide a further understanding of the present invention. The exemplary embodiments of the present invention and their descriptions are used to explain the present invention and do not constitute improper limitations on the present invention.

[0041] Figure 1 The results of ZNF514 significantly inhibiting the growth of LUAD organoid cells, where A is a schematic diagram of organoid generation from lung adenocarcinoma patients; B is a representative image of HE staining of lung adenocarcinoma tissues and related organoids from 3 patients; C is a representative image of IF staining, in which the molecular marker CK7 in LUAD organoids was observed; D is an immunohistochemical staining to detect the expression of CK7 and ZNF514 in lung adenocarcinoma patient tissues and related organoids; E is a representative image of LUAD organoids overexpressing GFP-EV and GFP-ZNF514; F is a representative bright field micrograph of LUAD organoids overexpressing GFP-EV and GFP-ZNF514 on days 1, 3, 5, 7, and 9; G is a quantitative analysis of organoid diameters at 5 different time points, showing that overexpression of GFP-ZNF514 significantly inhibited the growth of LUAD organoid cells (***P<0.001);

[0042] Figure 2 The results of low expression of ZNF514 in LUAD patients are associated with poor prognosis, where A is the difference in ZNF514 mRNA expression between normal and tumor tissues of LUAD from the TCGA database; B and C are the correlation between ZNF514 expression and pathological stage; D is a representative IHC image of ZNF514 expression in normal and tumor tissues of LUAD; E is the determination of ZNF514 protein levels in LUAD tumors and normal tissues by immunoblotting; F is the survival analysis of LUAD patients with high and low ZNF514 levels (***P<0.001);

[0043] Figure 3The results of ZNF514 inhibiting the proliferation and metastasis of lung adenocarcinoma in vitro and in vivo are shown in Figure 1. A is the qRT-PCR detection of ZNF514 mRNA levels in human bronchial epithelial cells (HBE) and lung adenocarcinoma cell lines; B is Western Protein expression of ZNF514 in LUAD cells was detected by blot, and C was quantified based on GAPDH for ZNF514; D-M were ZNF514 overexpressed in A549 and H1299 cells, and qRT-PCR (D) and western blot analysis (E) were performed on them; Transwell assay (F, H) and wound healing assay (J) were used to measure cell metastasis, and the migration and invasion data from three independent experiments were quantitatively analyzed (G, I); colony formation assay (K), EdU assay (L) and CCK-8 assay (M) were used to evaluate the effect of ZNF514 overexpression on cell proliferation; N-P were xenograft tumors established by injecting A549 vector (Vec) cells or A549 cells overexpressing ZNF514 into nude mice; subcutaneous tumors of nude mice were taken (N), weighed (O), and tumor volume was calculated (P) to evaluate the growth of LUAD cells in vivo; 2×10 6 cells formed tumors; Q is immunohistochemical staining used to evaluate the expression levels of ZNF514 and Ki67 in xenograft tumors (*P<0.05, **P<0.01, ***P<0.001);

[0044] Figure 4 Figure 2 shows the results of lung adenocarcinoma invasion and collagen-related pathways significantly correlated with ZNF514, where A to I are genes that were significantly downregulated and upregulated in A549-ZNF514 cells compared with A549-Vec cells detected by RNA sequencing; the volcano plot (A) shows the significant correlation between ZNF514-OE Significantly down-regulated and up-regulated genes in A549 cells, with a fold change of 2 and an adjusted p-value of 0.05; graphene oxide enrichment analysis diagram (B); KEGG analysis showing a bubble diagram of pathways with significantly changed expression (C); IPA analysis showing a bar diagram of related pathways of genes with significantly changed expression (D); gene set enrichment analysis (E, F); heat map showing that collagen family genes were significantly up-regulated in ZNF514-overexpressed A549 cells (G); J~K are qRT-PCR (H) and Western blotting (I) analysis of the ectopic expression of ZNF514 in A549 cells, and detection of the RNA and protein expression levels of ZNF514 and collagen family proteins; J is a ChIP experiment verifying the specific binding of ZNF514 to COL1A1 (*P<0.05, **P<0.01, ***P<0.001);

[0045] Figure 5The results show that COL1A1 plays an important role in the inhibition of lung adenocarcinoma proliferation and metastasis regulated by ZNF514, where A to G show ectopic expression of ZNF514 and / or COL1A1 in A549 and H1299 cells, respectively, and subsequent Western blotting analysis (A); Transwell assay (B, D) verifies the effects of ZNF514 and / or COL1A1 on the migration and invasion abilities of A549 and H1299 cells, and the migration and invasion data are quantitatively analyzed from three independent experiments (C, E); the proliferation abilities of A549 and H1299 cells ectopically expressing ZNF514 and / or COL1A1 are evaluated by clone formation assay (F) and EdU assay (G) (**P<0.01);

[0046] Figure 6 Figure 1 is the result of ZNF514 inhibiting lung adenocarcinoma progression and enhancing DDP sensitivity by targeting COL1A1, where A to B are the establishment of A549 / DDP cell line, and CCK-8 method was used to detect the resistance of A549 / DDP cell line and parental A549 cell line to DDP; C is the expression of ZNF514 in DDP-resistant A549 cells and parental A549 cells detected by qRT-PCR; C to E are Transwell assays to analyze the invasion ability of A549 cells transfected with NaCl or DDP (15 μg / mL) (D), and then the migration data of three independent experiments were quantitatively analyzed (E); F is A549 cells transfected or not transfected with ZNF514 were treated with NaCl or 15 μg / mL DDP, or treated with NaCl or 5 μg / mL Parental A549 cells transfected or not transfected with ZNF514 were treated with DDP, and then colony formation assay was performed; G-I: A549 / DDP cells transfected with ZNF514 or not transfected with ZNF514 were treated with NaCl or 15 μg / mL DDP for 24 h; transwell assay was used to detect cell migration and invasion ability (H); EdU assay (I) was used to evaluate cell proliferation (**P<0.01);

[0047] Figure 7 Figure 3 shows the results of ZNF514 inhibiting tumor progression and enhancing the sensitivity of lung adenocarcinoma to DDP by downregulating COL1A1 in vivo. A is a typical bright field micrograph of GFP-EV and GFP-OE-ZNF514 LUAD organoids treated with NaCl or 2 μg / mL DDP for 1, 3, 5, 7, and 9 days; B is a quantitative display of organoid size at 5 different time points. GFP-OE-ZNF514 combined with DDP treatment significantly inhibited the growth of LUAD organoids. Scale bar = 50 μm; C-E are nude mouse xenografts expressing ZNF514 or / and COL1A1 in A549 cells. All nude mice were subcutaneously injected with 2×10 6cells, when the tumor volume reaches about 100mm 3 Nude mice were randomly divided into two groups (n=6) and injected intraperitoneally with DDP (10 mg / Kg) or saline twice a week. The transplanted tumors (C) and tumor weights (D) were obtained after the nude mice were sacrificed on day 25. Tumor volume calculation: length × width 2 × 0.5 (E); F is IHC staining to evaluate the expression levels of ZNF514, COL1A1 and Ki67 xenograft tumors; G is a working model showing that ZNF514 enhances DDP sensitivity through the collagen signaling pathway, thereby inhibiting the proliferation and metastasis of lung adenocarcinoma. DETAILED DESCRIPTION

[0048] It should be noted that the following detailed descriptions are illustrative and are intended to provide further explanation of the present application. Unless otherwise specified, all technical and scientific terms used herein have the same meanings as those commonly understood by those skilled in the art to which the present application belongs.

[0049] It should be noted that the terms used herein are only for describing specific embodiments and are not intended to limit the exemplary embodiments according to the present application. As used herein, unless the context clearly indicates otherwise, the singular form is also intended to include the plural form. In addition, it should be understood that when the terms "comprise" and / or "include" are used in this specification, it indicates the presence of features, steps, operations, devices, components and / or combinations thereof.

[0050] The present invention is further described in conjunction with specific examples. The following examples are only for explaining the present invention and are not intended to limit the content thereof. If the specific experimental conditions are not specified in the examples, they are usually carried out according to conventional conditions or the conditions recommended by the reagent company; the reagents and consumables used in the following examples, unless otherwise specified, can all be obtained from commercial sources.

[0051] The present invention is further explained by the following examples, but they are not intended to limit the present invention. It should be understood that these examples are only used to illustrate the present invention and are not intended to limit the scope of the present invention. The test methods for the specific conditions in the following examples are usually carried out under normal conditions.

[0052] Example

[0053] Materials and methods

[0054] Tissue samples

[0055] The LUAD tissue and paired normal tissue used in the present invention were obtained from patients of Jinan Central Hospital Affiliated to Shandong First Medical University. Each patient underwent a thorough pathological examination to confirm the diagnosis of LUAD, and all patients signed informed consent before surgery. The present invention follows the guiding principles of the Declaration of Helsinki and has been approved by the Ethics Committee of Jinan Central Hospital Affiliated to Shandong First Medical University, with ethics approval number: SZR2022-77015-01. After collection, the samples were immediately frozen in liquid nitrogen and stored at -80°C for further use.

[0056] Cell lines, organoid culture, and transfection

[0057] Human bronchial epithelial cells (HBE) and human tumor cell lines A549, H1299, 95D, NCI-H1975, H838, H460, and PC-9 were obtained from Wuhan Purcell Life Science Technology Co., Ltd., China. All cell lines were cultured in DMEM supplemented with 10% fetal bovine serum and 1% penicillin-streptomycin solution and cultured for long periods of time at 37°C in a 5% CO2 incubator. The A549 / DDP cell line was cultured with 1 μg / mL DDP to maintain resistance to DDP. All cell lines were authenticated by short tandem repeat analysis and tested for mycoplasma every 6 months.

[0058] Six tissue samples were obtained from LUAD patients after surgery at Jinan Central Hospital Affiliated to Shandong First Medical University for organoid culture. LUAD tissues were cut into slices (1-2 mm) after surgery and treated with enzymes (collagenase D plus deoxyribonuclease I (DNase I)) at 37°C for 1 h. Floating tumor cells were collected by centrifugation, resuspended in Matrigel (Corning), seeded in 24-well plates, and expanded into three-dimensional organoids.

[0059] Three short hairpin RNAs (sh-RNAs) targeting ZNF514 were designed and synthesized by Genema Genetics (Shanghai, China). The following are the effective sequences of the target genes:

[0060] sh-ZNF514-1:

[0061] 5"CAGGUAGUAUCAGUGGAAATTUUUCCACUGAUACUACCUGTT-3";

[0062] sh-ZNF514-2:

[0063] 5"GGGAGAAGCUUAGGUUUAATTUUAAACCUAAGCUUCUCCCTT-3";

[0064] sh-ZNF514-3:

[0065] 5"CACACUUCAUCCCUUAUUATTUAAUAAGGGAUGAAGUGUGTT-3".

[0066] The ZNF514 overexpression plasmid was synthesized by Boshang Biotechnology (Jinan, China), and the COL1A1 plasmid was obtained from Fenghui Biotechnology (Hunan, China).

[0067] Before transfection, cells were cultured in 6-well plates until 60-90% confluence. Lipofectamine 3000 was used for transfection according to the instructions.

[0068] RNA extraction and real-time polymerase chain reaction (qRT-PCR)

[0069] According to the instructions, the present invention used TRIzol reagent to isolate total RNA from LUAD cell lines. cDNA synthesis was then performed using PrimeScript RT Reagent Kit (TaKaPa, Dalian, China) according to the protocol of the instructions. qRT-PCR was performed using SYBR Green Premix EX Taq (TaKaPa, Dalian, China). The primers used are shown in Table 1 below. All mRNA expression levels were calculated using the 2-ΔΔCt method and normalized to GAPDH expression.

[0070] Table 1 Primers used for RNA extraction and real-time polymerase chain reaction

[0071]

[0072]

[0073] Western Blotting

[0074] Cells were lysed using RIPA buffer supplemented with protease inhibitors, and protein samples were subsequently separated by SDS-PAGE and transferred to PVDF (Bio-Rad Laboratories) membranes. The membranes were blocked in 5% milk and Tris-buffered saline containing 0.05% Tween 20 for 2 h at room temperature. Target antigens were detected using specific antibodies and incubated overnight at 4 °C. The following antibodies were used: ZNF514 (YT6669; Parker Biotech, USA), COL1A1 (67288-1-Ig; Tri-Ting Biotech, Wuhan, China); N-cadherin (22018-1-AP; Tri-Ting Biotech, Wuhan, China), Vimentin (10366-1-AP), Snail 1 (13099-1-AP), and GAPDH (60004-1-Ig). The membranes were washed in TBST and incubated with HRP-labeled secondary antibodies for 1 h at room temperature. Signal detection was performed using an enhanced chemiluminescence (ECL) detection system. The density of the GAPDH band was used to normalize the density of the bands representing the specific proteins.

[0075] Healing experiment

[0076] For the scratch healing assay, cells were grown in 6-well plates. Subsequently, when the density reached confluence, a linear wound was scratched in the monolayer of cells using a pipette tip, the damaged cell layer was washed 3 times with PBS to remove debris, and the cells were further incubated with fresh medium containing 1% FBS. Cell images were collected at 0, 24, and 48 h.

[0077] Transwell experiment

[0078] Transwell assay was used to detect cell migration and invasion. 4 LUAD cells were added to the upper chamber, and the lower chamber was filled with medium containing 10% FBS. After 24 h, the cells that migrated to the lower chamber were fixed with 4% paraformaldehyde and stained with 0.1% crystal violet for 20 min at room temperature. The top layer of cells was then removed with a cotton swab, and images of the migrating cells were captured using an optical microscope. Cells were quantitatively analyzed using ImageJ.

[0079] Cell counting kit-8 (CCK-8) assay

[0080] To evaluate the proliferation capacity of LUAD cells, CCK-8 kit (Beyotime, Beyotime, Jiangsu, China) was used for detection according to the manufacturer's guidelines. 3Cells were seeded in 96-well plates overnight. After incubation for 0, 24, 48, 72, 96, and 120 hours, 10 μL of CCK-8 solution was added to each well. Finally, the absorbance value (450 nm) was measured using an ELISA reader.

[0081] The resistance of LUAD cells to DDP was analyzed using a commercial CCK8 kit. Transfected LUAD cells were treated with 0, 1, 2, 4, 8, 16, 32, or 64 μg / mL of DDP. LUAD cells were incubated with 10 μL of CCK8 reagent for 1 hour. Cell viability was measured at 450 nm, and the half inhibitory concentration (IC50) was calculated.

[0082] Colony formation assay

[0083] Cells (1000 cells / well) were seeded into 6-well plates and incubated in DMEM supplemented with 10% FBS at 37° C. After 14 days of culture, cell colonies were fixed with 4% paraformaldehyde and then stained with 0.1% crystal violet for 20 min.

[0084] 5-Ethynyl-2'deoxyuridine (EdU) assay

[0085] EdU proliferation assay was performed by using Cell Light EdU Apollo 567 in vitro imaging kit according to the manufacturer's instructions. 3 Cells / well) were seeded into 96-well plates. After 24 h, 100 μL of culture medium containing 50 μM EdU was added to each well and then incubated at 37 °C for 2 h. Then, the cells were fixed with 4% paraformaldehyde and stained with a combination of Hoechst and Apollo reaction mixture. Images were captured using a fluorescence microscope and processed and compiled using Adobe Photoshop software. All experimental procedures were repeated at least three times.

[0086] Immunohistochemistry (IHC)

[0087] Formalin-fixed and paraffin-embedded LUAD samples were incubated with primary antibodies against ZNF514 (1:20 00 dilution), COL1A1 (1:400 dilution), Ki-67 (1:200 dilution) and cytokeratin 7 (1:2000 dilution) at 4 °C overnight and then incubated with immunoglobulin G (IgG) / horseradish peroxidase (HRP) polymer (ZSGB-BIO) and diaminobenzidine substrate (ZSGB-BIO) according to the manufacturer’s protocol.

[0088] Immunofluorescence (IF) staining

[0089] PDO were fixed with 4% paraformaldehyde for 15 minutes at room temperature. Then, sections were subjected to IF assay. After washing 3 times, cells were permeabilized with 0.1% Triton X-100 and blocked with 1% goat serum for 1 h. Antibodies used for staining were as follows: Cytokeratin 7 (1:400 dilution).

[0090] Xenograft tumor models

[0091] 48 5-week-old male BALB / c nude mice were purchased from Vital River Laboratory Animal Technology Company. All nude mice were injected subcutaneously with 2×10 6 When the tumor volume reaches about 100mm 3 At the same time, the mice in each group were randomly divided into a control group and an experimental group, and normal saline or DDP (10 mg / kg, DDP was diluted with normal saline) was intraperitoneally injected twice a week. The tumor volume was measured with a caliper twice a week, and the calculation formula was: V = 1 / 2 × length × width 2. 30 days after inoculation, the tumor was weighed. All animal experiments were performed in accordance with the guidelines of the Animal Experiment Ethics Committee of Jinan Central Hospital.

[0092] Ingenuity PathwayAnalysis(IPA)

[0093] The deg list containing gene identifiers and corresponding expression values ​​in A549 e-ZNF514 cells was uploaded to Ingenuity Pathway Analysis (IPA) software (QIAGEN, California, USA). The "core analysis" function in the software was used to analyze the differential expression data, including biological processes, canonical pathways, upstream transcriptional regulators, and gene network correlation analysis.

[0094] Statistical analysis

[0095] GraphPad Prism 8.4.3 was used to analyze and plot the data. All experiments were performed at least 3 times. The t-test was used for comparison between the two groups, and one-way or two-way analysis of variance (95% CI) was used for multiple comparisons. Kaplan-Meier curves were used for survival analysis, and logrank tests were used for comparison between groups. P<0.05 (*), P<0.01 (**), P<0.001 (***).

[0096] Experimental results:

[0097] Result 1: ZNF514 was lowly expressed in both organoids and parental tumors, and ZNF514 significantly inhibited the progression of lung adenocarcinoma.

[0098] Given that 3D organoids can fully retain the genetic and phenotypic characteristics of their parental tumors, the present invention cultured organoids from three different LUAD patients for further research. The schematic diagram of the generation of LUAD organoids is shown in the figure below. Figure 1 As shown in A. Hematoxylin and eosin (HE) staining was used to determine the origin of LUAD organoids. The results showed histological similarities between LUAD organoids and their respective parental tumors ( Figure 1 In addition, IF staining of cytokeratin 7 (CK7), a widely recognized LUAD-specific marker, was performed. The results showed significantly high CK7 expression, indicating that the tumor organoids fully retained the molecular pathological characteristics of the LUAD tissue from which they were derived ( Figure 1 In addition, IHC staining was performed on the organoids and their corresponding parental tumors. These results further validated the successful construction of LUAD organoids, as both organoids and parental tumors showed positive staining for CK7. In addition, ZNF514 was lowly expressed in both organoids and parental tumors ( Figure 1 In D), to further explore the effect of ZNF514 on the growth of LUAD, 5×10 8 Surprisingly, more than 80% of the organoids showed green fluorescence, indicating effective lentiviral infection ( Figure 1 Middle E). The study showed that overexpression of ZNF514 led to significant inhibition of LUAD organoid growth compared with the control group (vec) ( Figure 1 Based on these findings, it can be determined that ZNF514 plays a tumor suppressor role in LUAD. However, the exact mechanism by which ZNF514 participates in the development of LUAD is still unclear and requires further studies to fully understand it.

[0099] Result 2: ZNF514 expression was downregulated in LUAD and was associated with poor prognosis of LUAD patients.

[0100] Given that ZNF514 has a significant inhibitory effect on the proliferation of LUAD organoids, we further explored the potential role of ZNF514 in the progression of LUAD. The TCGA (The cancer genome atlas) database showed that ZNF514 expression in LUAD tissues was significantly reduced compared with normal tissues ( Figure 2 In addition, we investigated the correlation between ZNF514 mRNA expression and TNM stage in LUAD patients and found that ZNF514 expression was negatively correlated with cancer stage ( Figure 2 Similarly, in the lymph node metastasis group, the mRNA level of ZNF514 was downregulated in LUAD ( Figure 2In addition, IHC results showed that the ZNF514 protein level in LUAD tumor tissues was significantly lower than that in adjacent non-tumor tissues ( Figure 2 Western blotting analysis of 6 pairs of paired tumors and adjacent non-tumor tissues confirmed that the expression of ZNF514 in tumor tissues was low ( Figure 2 In addition, Kaplan-Meier (KM) Plotter showed that high mRNA expression of ZNF514 was significantly correlated with increased overall survival in LUAD patients, with a hazard ratio (HR) of 0.69 and a log-rank P value of 0.00071 ( Figure 2 F). Therefore, the evidence shows that ZNF514 is downregulated in LUAD and can be used as a diagnostic marker for LUAD and used to prepare products for diagnosis, detection, monitoring or prediction of LUAD progression. It also suggests that ZNF514 can act as a tumor suppressor and play a role in inhibiting the progression of LUAD.

[0101] Result 3: ZNF514 can inhibit the proliferation and metastasis of LUAD both in vivo and in vitro.

[0102] To further investigate the potential function of ZNF514 in LUAD, its expression in LUAD cell lines was preliminarily detected. The results showed that compared with human bronchial epithelial-like cells (HBE), the mRNA and protein expression of ZNF514 were significantly downregulated in all tested LUAD cell lines ( Figure 3 A to C in the figure). Stable cell lines with overexpression or underexpression of ZNF514 were successfully generated in A549 and H1299 cells. qRT-PCR and Western blotting analysis showed that the mRNA and protein expressions of ZNF514 were significantly increased in the cell lines overexpressing ZNF514 ( Figure 3 D-E). Transwell assays with and without Matrigel and wound healing assays showed that overexpression of ZNF514 led to significant inhibition of migration and invasion of A549 and H1299 cells ( Figure 3 These findings suggest that ZNF514 plays a key role in inhibiting LUAD cell migration and invasion. To gain a deeper understanding of the role of ZNF514 in LUAD cell proliferation, EdU, CCK-8, and colony formation experiments were performed. The results showed that overexpression of ZNF514 significantly impaired the proliferation of A549 and H1299 cells ( Figure 3 These results indicate that ZNF514 plays a crucial role in regulating the metastasis and proliferation of LUAD cells in vitro.

[0103] To investigate the role of ZNF514 in tumorigenesis in vivo, 2 × 10 6 A549 cells overexpressing ZNF514 or the vector were subcutaneously inoculated into BALB / c nude mice. The results showed that overexpression of ZNF514 could inhibit tumor growth ( Figure 3 In addition, IHC staining showed that the expression of Ki67 was significantly decreased ( Figure 3 In summary, these findings provide strong evidence that ZNF514 inhibits the growth and migration of LUAD cells in vivo and in vitro.

[0104] Result 4: RNA sequencing showed that ZNF514 significantly downregulated the expression of collagen

[0105] To explore the mechanism of ZNF514 involvement in LUAD tumor growth and progression, RNA sequencing (RNA-seq) analysis was performed. Volcano plot ( Figure 4 Middle A) shows that there are 34 significantly upregulated genes and 52 significantly downregulated genes. Graphene oxide enrichment analysis showed that these genes were mostly enriched in cell adhesion, cadherin binding and regulatory protein complex assembly, which is similar to the results of in vitro experiments ( Figure 4 In addition, KEGG enrichment analysis also showed that ZNF514 overexpression affected many cancer-related signaling pathways, such as PI3K-AKT, JAK-STAT, NF-κB, and ECM receptor interaction signaling pathways ( Figure 4 Middle C). IPA was used to evaluate the enrichment of ZNF514-related classical pathways. DEGs were most significantly enriched in the wound healing signaling pathway ( Figure 4 In addition, gene set enrichment analysis (GSEA) revealed a significant negative correlation between ZNF514 expression and wound healing signaling pathways ( Figure 4 GSEA further confirmed that there was a significant negative correlation between ZNF514 expression and the extracellular matrix (ECM) and collagen pathways ( Figure 4 Middle F). Figure 2 showed that high collagen expression was associated with poor prognosis in LUAD patients. Figure 4 Middle G shows that collagen was significantly downregulated after ZNF514 overexpression. qRT-PCR and western blotting also showed that COL1A1, COL4A1, COL4A2, COL5A1, and COL7A1 were significantly downregulated in the ZNF514 ectopic expression group ( Figure 4 H~I in the middle). The prior art shows that collagen is considered to be a key role in the pathogenesis of lung adenocarcinoma due to its fibrotic properties. And multiple evidences have consistently shown that COL1A1 plays a key role in promoting cancer cell proliferation, adhesion and migration, inducing matrix remodeling, and promoting LUAD progression and drug resistance.

[0106] Therefore, we focused on COL1A1 for further research. ChIP assay results showed that ZNF514 directly binds to the COL1A1 promoter region and inhibits its transcription ( Figure 4 Therefore, we propose that ZNF514 affects the development of LUAD by targeting the wound healing signaling pathway. In addition, these findings suggest that COL1A1 may play a key role as a downstream target of ZNF514 in the progression of LUAD.

[0107] Result 5: COL1A1 is a downstream target gene of ZNF514.

[0108] To further evaluate whether ZNF514 participates in the proliferation, migration, and invasion of LUAD by targeting COL1A1, experimental validation was performed. Western blotting analysis showed that ectopic expression of ZNF514 in A549 and H1299 cells led to a significant decrease in COL1A1. Interestingly, when COL1A1 was co-overexpressed with ZNF51413, the inhibitory effect of ectopic expression of ZNF514 on EMT was reversed. These findings highlight the important role of ZNF514 in inhibiting EMT in A549 and H1299 cells, mainly by inhibiting the expression of COL1A1 ( Figure 5 In addition, Transwell assays showed that overexpression of COL1A1 significantly promoted the migration and invasion of A549 and H1299 cells. However, this effect was effectively abolished when ZNF514 was overexpressed together with COL1A1 ( Figure 5 On the other hand, the number of colonies in cells overexpressing ZNF514 decreased, while these effects disappeared simultaneously after overexpression of COL1A1. EdU experiments also showed that COL1A1 restored the inhibitory effect of ZNF514 on cell growth ( Figure 5 In summary, the results showed that ZNF514 inhibited the proliferation, migration and invasion of LUAD cells by targeting COL1A1.

[0109] Result 6: ZNF514 inhibited tumor progression of LUAD cells and enhanced cisplatin sensitivity by targeting COL1A1.

[0110] Recent studies have highlighted that COL1A1 contributes to chemoresistance in multiple cancer types, and targeted reduction of COL1A1 may be an effective strategy to overcome chemoresistance in LUAD. Based on the above experimental results, ZNF514 can regulate LUAD resistance to DDP through COL1A1. To investigate the relationship between ZNF514 and DDP resistance in LUAD, a DDP-resistant LUAD cell line (A549 / DDP) was established. First, the CCK-8 assay was used to evaluate the half-maximal inhibitory concentration (IC50) values ​​of DDP-sensitive cells (A549) and DDP-resistant cells (A549 / DDP). Figure 6 The IC50 value for A549 cells was 4.77 μg / mL, and the IC50 value for A549 / DDP cells was 16.58 μg / mL, which strongly indicated that the establishment of DDP-resistant LUAD cell line was successful ( Figure 6 In addition, compared with the DDP-sensitive A549 cell line, the expression of ZNF514 was significantly downregulated in A549 / DDP cells ( Figure 6 These findings suggest that ZNF514 may play an important role in the development of DDP resistance in LUAD cells. In addition, Transwell assays showed that combined treatment of ZNF514 with DDP resulted in a greater reduction in cell migration compared with ZNF514 overexpression or DDP treatment alone ( Figure 6 Further experiments showed that A549 and A549 / DDP cells overexpressing ZNF514 were more sensitive to DDP than cells transfected with the vector, and colony formation was reduced ( Figure 6 In order to further verify whether ZNF514 regulates the resistance of A549 / DDP cells to DDP through COL1A1, rescue experiments were performed. The experiment showed that rescuing the expression of COL1A1 in A549 / DDP cells reversed the inhibitory effect of ZNF514 on LUAD cell proliferation, migration and DDP resistance ( Figure 6 Collectively, these data suggest that ZNF514 can mediate COL1A1 silencing in DDP-resistant LUAD cells to overcome resistance and resensitize cells to cisplatin treatment.

[0111] Result 7: ZNF514 downregulates COL1A1 to inhibit tumor progression and improve cisplatin sensitivity of LUAD in vivo.

[0112] Cell experiments showed that overexpression of ZNF514 significantly inhibited the proliferation and metastasis of LUAD cells in vitro and reversed cisplatin resistance by targeting COL1A1. Therefore, in order to further verify the role of ZNF514 in regulating drug resistance, LUAD organoids were treated simultaneously with lentivirus overexpressing ZNF514 and DDP. As expected, overexpression of ZNF514 significantly inhibited the growth of organoids. In addition, the LUAD organoids in the DDP-only treatment group disintegrated and died on the 7th day, while this disintegration was observed as early as the 5th day in the ZNF514-overexpression group and the DDP-treated group ( Figure 7 Therefore, the results based on the preclinical model further showed that ZNF514 enhanced the sensitivity of LUAD to DDP, and the combination of the two treatments was more effective. To further verify the effect of ZNF514 in vivo, a xenograft model was established, and it was found that the combination of ZNF514 and DDP (10 mg / kg; twice a week) resulted in smaller tumor volume and lower proliferation index Ki-67 compared with mice treated with ZNF514 or DDP alone ( Figure 7 Middle C~F).

[0113] The study showed that ZNF514 contributes significantly to DDP resistance. Mechanistically, ZNF514 directly binds to the COL1A1 promoter and downregulates COL1A1. In addition, ZNF514 overexpression can inhibit EMT by inhibiting COL1A1 in LUAD, thereby reversing cisplatin resistance. Importantly, the results reveal the role of the ZNF514 / COL1A1 signaling pathway in LUAD DDP resistance, and targeting this signaling pathway would be a potential method to reverse LUAD DDP resistance ( Figure 7 Middle G).

Claims

1. Use of a detection reagent for detecting the expression level of the ZNF514 gene and its expression product in the preparation of a kit for diagnosing lung adenocarcinoma.

2. Use of a plasmid overexpressing ZNF514 in at least one of the following b1)-b2): b1) Preparation of a medicament for treating lung adenocarcinoma; b2) Combined with cisplatin to prepare a drug for treating lung adenocarcinoma.

3. Use of a composition in at least one of the following b1) to b2): b1) Preparation of a medicament for treating lung adenocarcinoma; b2) Combined with cisplatin to prepare a drug for treating lung adenocarcinoma; The composition comprises a plasmid overexpressing ZNF514, and the plasmid is the only active ingredient in the composition.